Zeger G, Smith L, McQuiston D, Goldfinger D
Taft B. Schreiber Blood Bank, Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, California.
Transfusion. 1988 Sep-Oct;28(5):493-5. doi: 10.1046/j.1537-2995.1988.28588337345.x.
Antibodies to cisplatin, an extensively used anticancer chemotherapeutic agent, have been implicated previously as a cause of immune hemolytic anemia. Investigation of a suspected case of cisplatin-induced hemolytic anemia in a 40-year-old man demonstrated that IgG could be adsorbed nonimmunologically by reagent red cells in vitro. This phenomenon was found to be a source of possible error in the interpretation of studies identifying specific cisplatin antibodies. Furthermore, cisplatin was found to be capable of producing a positive direct antiglobulin test (DAT), owing to the nonspecific adsorption of immunoglobulin and complement in vivo. Although this finding did not result in acute hemolysis, it may cause confusion in the investigation of DAT-positive hemolytic anemias. We question whether previous reports of cisplatin-induced hemolytic anemia are accurate in their assessment that such hemolysis was mediated immunologically. Future studies of suspected cases of hemolysis induced by this drug should include serologic investigation adequate to demonstrate the presence of specific cisplatin antibodies. A positive DAT in such patients should not be considered proof of drug-induced immune hemolytic anemia.
顺铂是一种广泛使用的抗癌化疗药物,此前已有研究表明,针对顺铂的抗体是免疫性溶血性贫血的一个病因。对一名40岁男性疑似顺铂诱导的溶血性贫血病例的调查显示,IgG在体外可被试剂红细胞非免疫性吸附。这一现象被发现是在鉴定特异性顺铂抗体的研究解释中可能出现误差的一个来源。此外,发现顺铂能够产生阳性直接抗球蛋白试验(DAT),这是由于免疫球蛋白和补体在体内的非特异性吸附所致。虽然这一发现并未导致急性溶血,但可能会在DAT阳性溶血性贫血的调查中造成混淆。我们质疑先前关于顺铂诱导的溶血性贫血的报告在评估这种溶血是由免疫介导的方面是否准确。对该药物诱导的疑似溶血病例的未来研究应包括足够的血清学调查,以证明特异性顺铂抗体的存在。此类患者的阳性DAT不应被视为药物诱导的免疫性溶血性贫血的证据。